What’s happening in neuro device investing? In a new SVB sub-sector report we cover the private companies that are developing devices to treat neurological diseases, as well as non-neuro diseases in which the therapeutic effect is mediated through the nervous system.

Key insights from the report:

  • Financings increased by over 40 percent and invested equity grew by over 50 percent from 2016 to 2017.
  • Nervous system diseases — including pain, epilepsy and movement disorders, among others — represented the largest disease focus for neuro devices, capturing 40-45 percent of financings in both 2016 and 2017.
  • Significant early-stage investment took place, with 16 Seed and Series A financings raising more than $10 million each.

Download the report to learn more

About the Author

Bill Sideris is a Senior Associate with SVB Securities, conducting M&A advisory engagements involving early stage, venture-backed companies in the Healthcare and Life Sciences sectors. Prior to joining SVB Securities, Bill Sideris developed medical devices for ophthalmic and cardiovascular indications in both Fortune 500 and start-up organizations.

Bill Sideris graduated with a Professional Doctorate degree in engineering from the Technical University of Delft and a Master of Science degree in biomedical engineering from the University of Houston.
Now Let's Get Started

See how SVB makes next happen now for entrepreneurs like you.

Connect with Us